KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Ensemble Deep Learning-Based High-Precision Framework for Breast Cancer Detection from Histopathological Images. PMID 41827929 · Diagnostics (Basel) · 2026-Feb-24 The record describes a methodological study in deep learning for breast cancer diagnosis from images. It is not a randomized clinical trial, lacks a drug intervention, and does not report any time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of cerebral oxygenation-guided resuscitation during immediate postnatal transition on brain injury and brain growth detected by MRI in very preterm neonates: a secondary outcome analysis of the multicenter randomized phase 3 clinical COSGOD III trial. PMID 41736052 · Ital J Pediatr · 2026-Feb-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial. PMID 41735896 · BMC Cancer · 2026-Feb-24 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Protocol for the development and testing of a web-based patient decision aid for early-stage breast cancer patients within a cancer centre care: a mixed-method approach. PMID 41734922 · BMJ Open · 2026-Feb-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. PMID 41733109 · Arthritis Rheumatol · 2026-Feb-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. PMID 41730847 · Signal Transduct Target Ther · 2026-Feb-24 The record describes a secondary analysis of a randomized trial evaluating molecular profiling (including DNA and RNA profiling) for guiding cancer therapy, with overall survival (OS) as a time-to-event endpoint. However, the trial is described as a 'randomized study' (NCT02152254) without explicit mention of Phase III/IIIb or Phase II/III status, and the analysis focuses on concordance between profiling methods and correlates gene expression with OS, not the primary efficacy of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: A Randomized Clinical Trial. PMID 41468027 · JAMA · 2026-Feb-24 While this is an original, randomized oncology trial in humans, it does not meet two key eligibility criteria: 1) It lacks a time-to-event primary/key secondary efficacy endpoint (OS, PFS, DFS, etc.), and 2) The intervention is non-drug (symptom assessment via health workers).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial. PMID 41972014 · Liver Cancer · 2026-Feb-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Conventional Versus Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumors ≤ 20 mm: Study Protocol for a Multicenter Randomized Controlled Trial (D-CURE Trial). PMID 41745223 · Methods Protoc · 2026-Feb-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ultrasound-guided retro-superior costotransverse ligament space block (RSSB) versus subcostal transversus abdominis plane block (TAPB) for postoperative analgesia in gastric cancer patients undergoing laparoscopic gastrectomy : a prospective randomized controlled trial. PMID 41724933 · BMC Anesthesiol · 2026-Feb-23 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo. PMID 41756446 · Res Sq · 2026-Feb-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis. PMID 41749963 · Cancers (Basel) · 2026-Feb-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis. PMID 41722967 · Lancet · 2026-Feb-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial. PMID 41655588 · Lancet · 2026-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. PMID 41653933 · Lancet · 2026-Feb-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial]. PMID 41975647 · Zhongguo Fei Ai Za Zhi · 2026-Feb-20 Record meets criteria for oncology, human, randomized trial with drug intervention and time-to-event efficacy endpoints (PFS, OS) as primary/secondary outcomes. However, metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. Without this confirmation, is_eligible must be false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study. PMID 41721054 · Pediatr Res · 2026-Feb-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. PMID 41499716 · J Clin Oncol · 2026-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. PMID 41363770 · J Clin Oncol · 2026-Feb-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation. PMID 41715172 · Pilot Feasibility Stud · 2026-Feb-19 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol. PMID 41715140 · Trials · 2026-Feb-19 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravenous Fosfomycin in Complicated Urinary Tract Infection. PMID 41711122 · Ann Pharmacother · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials. PMID 41175364 · Blood · 2026-Feb-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease. PMID 41708985 · J Neurol · 2026-Feb-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Elderly Patients with Cancer Bone Metastases: A Target Trial Emulation Study. PMID 41752980 · Life (Basel) · 2026-Feb-17 The record describes a retrospective observational cohort study (target trial emulation) comparing denosumab to bisphosphonates. While it is an oncology study with a time-to-event endpoint and drug intervention, it does not meet the core eligibility requirement of being a randomized controlled trial (Phase III/IIIb or Phase II/III). The abstract explicitly states it is a retrospective cohort study, not a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. PMID 41707646 · Cell Rep Med · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration. PMID 41703113 · Sci Rep · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial. PMID 41702946 · Sci Rep · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Enhancing palliative care in intensive care units: protocol of EPIC, a controlled, cluster-randomised, non-blinded stepped-wedge design trial with crossover phase. PMID 41702660 · BMJ Open · 2026-Feb-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evidence-Based Self-Management Strategies for Fibromyalgia: Foundations for Digital Therapeutic Applications. PMID 41701966 · Interact J Med Res · 2026-Feb-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. PMID 41537692 · Clin Cancer Res · 2026-Feb-17 The record is a secondary, biomarker-focused analysis (MRD) within a larger randomized trial (NADIM II). While it originates from a trial with oncology, human, randomized, drug intervention, and time-to-event components, this specific publication does not present the primary efficacy results of the parent trial. It is a secondary/prognostic analysis. The parent trial's phase is not explicitly confirmed in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial. PMID 41378996 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. PMID 41378992 · Clin Cancer Res · 2026-Feb-17 The record describes a randomized, drug-intervention trial in human oncology with a time-to-event endpoint (PFS). However, two key criteria for eligibility cannot be definitively established from the provided metadata: 1) The formal trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the title, abstract, or metadata, though the title mentions 'late-phase' and the abstract notes it as a completed efficacy trial. 2) The report is a secondary/biomarker analysis ('exploratory analysis') of the GOG281/LOGS trial, not the primary formal-result report of the trial's main efficacy findings. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial. PMID 41364689 · JAMA · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. PMID 41360717 · JAMA · 2026-Feb-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial. PMID 41335375 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial. PMID 41754168 · Nutrients · 2026-Feb-16 The study is a randomized, open-label, pilot trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial. The primary and secondary endpoints (postoperative complications, mortality at 1 month, length of stay) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). The intervention is nutritional supplementation, not a drug intervention. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial. PMID 41698721 · BMJ Open · 2026-Feb-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Understanding the Unique Ethical Challenges in Randomized Controlled Trials of Delirium Interventions for Older Adults: A Rapid Review. PMID 41698182 · Anesth Analg · 2026-Feb-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Influence of gemcitabine combined with lobaplatin interventional embolization on vaginal flora and biofilm formation in patients with advanced cervical cancer. PMID 41697076 · Afr J Reprod Health · 2026-Feb-16 The study is an oncology randomized trial with a drug intervention, but the reported outcomes (vaginal flora changes, biofilm formation, and general 'curative effect') do not include a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, or Kaplan-Meier analysis. Therefore, it does not meet the eligibility criteria for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Control arm overperformance in phase 3 oncology clinical trials. PMID 41653086 · Cancer · 2026-Feb-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial. PMID 41137194 · Int J Cancer · 2026-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be? PMID 41753185 · J Clin Med · 2026-Feb-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of a novel sodium picosulfate oral tablet in a randomized controlled trial for bowel preparation. PMID 41695285 · World J Gastroenterol · 2026-Feb-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE). PMID 41689093 · Radiat Oncol · 2026-Feb-14 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. PMID 41689066 · Trials · 2026-Feb-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial. PMID 41628627 · Lancet · 2026-Feb-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial. PMID 41692352 · Int J Radiat Oncol Biol Phys · 2026-Feb-13 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset. PMID 41072954 · J Neurol Neurosurg Psychiatry · 2026-Feb-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. PMID 41836917 · Breast Care (Basel) · 2026-Feb-12 The record describes a retrospective subgroup analysis of the WSG-ADAPT-HR+/HER2- trial, which is not explicitly identified as a Phase III or Phase II/III trial for the drug intervention in question. The analysis integrates recurrence score and endocrine responsiveness to refine risk assessment, projecting theoretical benefit from other trials (NATALEE, monarchE) rather than reporting primary results of a randomized drug intervention comparison. While the parent trial may be randomized and involve drugs, this specific report is a secondary subgroup analysis, not a primary or definitive result report of the trial's drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -